UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1

Biochemical journal, 2012-05, Vol.444 (1), p.79-88

2012

Volltextzugriff (PDF)

Discovery of a Potent and Selective Sphingosine Kinase 1 Inhibitor through the Molecular Combination of Chemotype-Distinct Screening Hits

Journal of medicinal chemistry, 2017-03, Vol.60 (6), p.2562-2572

2017

Volltextzugriff (PDF)

Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models

Molecular cancer therapeutics, 2018-10, Vol.17 (10), p.2144-2155

2018

Volltextzugriff (PDF)

High-throughput screening assay for sphingosine kinase inhibitors in whole blood using RapidFire® mass spectrometry

Journal of biomolecular screening, 2011-02, Vol.16 (2), p.272-277

2011

Volltextzugriff (PDF)

Characterization of the Cytoprotective Action of Peroxynitrite Decomposition Catalysts

The Journal of biological chemistry, 1998-06, Vol.273 (25), p.15646-15653

1998

Volltextzugriff (PDF)

Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance

Cancer research (Chicago, Ill.), 2023-09, Vol.83 (17), p.2839-2857

2023

Volltextzugriff (PDF)

Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression

Nature communications, 2020-05, Vol.11 (1), p.2156-13, Article 2156

2020

Volltextzugriff (PDF)

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

Cancer research (Chicago, Ill.), 2023-09, Vol.83 (17), p.2839-2857

2023

Volltextzugriff (PDF)

Abstract 2828: Combining neratinib with trastuzumab deruxtecan to treat HER2;TP53 co-mutated breast cancers

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.2828-2828

2024

Volltextzugriff (PDF)

Abstract PS4-13: Irreversible inhibition of HER2 activating mutations with neratinib enhances the pre-clinical efficacy of trastuzumab emtansine and trastuzumab deruxtecan

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS4-13-PS4-13

2021

Volltextzugriff (PDF)

Abstract 2375: Concurrent HER or PI3K inhibition potentiates the anti-tumor effect of ERK inhibitor BVD-523 (ulixertinib) in preclinical pancreatic cancer models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2375-2375

2018

Volltextzugriff (PDF)

Abstract 4527: Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, nonamplified metastatic breast cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4527-4527

2019

Volltextzugriff (PDF)

Concurrent HER or PI3K Inhibition Potentiates the Anti-tumor Effect of ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models

Molecular cancer therapeutics, 2018-07, Vol.17 (10), p.2144-2155

2018

Volltextzugriff (PDF)

Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene A4 hydrolase

Bioorganic & medicinal chemistry letters, 2003-03, Vol.13 (6), p.1137-1139

2003

Volltextzugriff (PDF)

Synthesis of Potent Leukotriene A4 Hydrolase Inhibitors. Identification of 3-[Methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic Acid

Journal of medicinal chemistry, 2002-08, Vol.45 (16), p.3482-3490

2002

Volltextzugriff (PDF)

Abstract 5778: Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6 -Cyclin D1 axis driving tumorigenesis and drug resistance

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5778-5778

2023

Volltextzugriff (PDF)

Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer

Journal of gastrointestinal oncology, 2019-06, Vol.10 (3), p.412-420

2019

Volltextzugriff (PDF)

Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.763-763

2015

Volltextzugriff (PDF)

Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A4 hydrolase

Bioorganic & medicinal chemistry letters, 2002-12, Vol.12 (23), p.3383-3386

2002

Volltextzugriff (PDF)

Infection of the Basal Ganglia by a Murine Coronavirus

Science (American Association for the Advancement of Science), 1985-08, Vol.229 (4716), p.877-879

1985

Volltextzugriff (PDF)

Synthesis of potent leukotriene A(4) hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid

Journal of medicinal chemistry, 2002-08, Vol.45 (16), p.3482-3490

2002

Volltextzugriff (PDF)

High Level, Stable Production of Recombinant Proteins in Mammalian Cell Culture using the Herpesvirus VP16 Transactivator

Bio/technology (New York, N.Y. 1983), 1993-09, Vol.11 (9), p.1037-1041

1993

Volltextzugriff (PDF)

O28. NO biomarkers: Windows to NO-mediated pathology and therapeutic intervention

Nitric oxide, 2006-06, Vol.14 (4), p.9-9

2006

Volltextzugriff (PDF)

Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolase

Bioorganic & medicinal chemistry letters, 2002-12, Vol.12 (23), p.3383

2002

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1

Discovery of a Potent and Selective Sphingosine Kinase 1 Inhibitor through the Molecular Combination of Chemotype-Distinct Screening Hits

Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models

High-throughput screening assay for sphingosine kinase inhibitors in whole blood using RapidFire® mass spectrometry

Characterization of the Cytoprotective Action of Peroxynitrite Decomposition Catalysts

Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance

Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

Abstract 2828: Combining neratinib with trastuzumab deruxtecan to treat HER2;TP53 co-mutated breast cancers

Abstract PS4-13: Irreversible inhibition of HER2 activating mutations with neratinib enhances the pre-clinical efficacy of trastuzumab emtansine and trastuzumab deruxtecan

Abstract 2375: Concurrent HER or PI3K inhibition potentiates the anti-tumor effect of ERK inhibitor BVD-523 (ulixertinib) in preclinical pancreatic cancer models

Abstract 4527: Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, nonamplified metastatic breast cancer

Concurrent HER or PI3K Inhibition Potentiates the Anti-tumor Effect of ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models

Structure−Activity Relationship Studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a Potent Inhibitor of Leukotriene A4 (LTA4) Hydrolase

Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene A4 hydrolase

Synthesis of Potent Leukotriene A4 Hydrolase Inhibitors. Identification of 3-[Methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic Acid

Abstract 5778: Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6 -Cyclin D1 axis driving tumorigenesis and drug resistance

Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer

Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer

Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A4 hydrolase

Infection of the Basal Ganglia by a Murine Coronavirus

Synthesis of potent leukotriene A(4) hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid

High Level, Stable Production of Recombinant Proteins in Mammalian Cell Culture using the Herpesvirus VP16 Transactivator

O28. NO biomarkers: Windows to NO-mediated pathology and therapeutic intervention

Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolase

Suchergebnisse filtern